GET DAILY SIGNALSOncolytics Biotech (ONCY): Tracking Pelareorep's Progress in Cancer Immunotherapy
Key Takeaways
- Oncolytics Biotech Inc. (ONCY) is a clinical-stage biopharmaceutical company focused on cancer immunotherapy.
- The company's lead candidate is pelareorep, an intravenously delivered, double-stranded RNA immunotherapeutic agent.
- Its development programs center on gastrointestinal cancers, including pancreatic, colorectal, and anal cancers, as well as breast cancer.
- The company is pre-revenue and has incurred operating losses since inception, a common profile for early-stage biotechnology firms.
- Pelareorep has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for colorectal and pancreatic cancer.
Company Overview
Oncolytics Biotech Inc. operates as a clinical-stage biotechnology firm developing treatments through a virus-derived immunotherapy platform. I follow ONCY because it offers exposure to a novel oncology strategy: an engineered agent intended to activate the immune system against tumors. As a development-stage entity, its valuation depends more on clinical trial outcomes and regulatory steps than on current financial results.
The company was incorporated on April 2, 1998, under Alberta's Business Corporations Act. In 2026 it completed a domestication to Nevada. Headquarters sit in San Diego at 4350 Executive Drive, Suite 325. Shares trade on the Nasdaq Capital Market under ONCY, and the firm employs roughly 29 people full time.
The Science Behind Pelareorep
Oncolytics remains in the clinical stage, so its candidates have not yet secured full regulatory approval for sale. The business centers on advancing pelareorep toward potential approvals and partnerships. The company generates little or no product revenue at present.
Pelareorep is positioned as an intravenously delivered, double-stranded RNA immunotherapeutic. Its proposed action involves activating both innate and adaptive immune responses while reducing tumor defenses, aiming to turn immunologically cold tumors hot and more responsive to other treatments.
Pipeline Focus and Regulatory Status
The primary emphasis lies on gastrointestinal tumors. Ongoing studies target metastatic pancreatic cancer, second-line or later anal cancer, metastatic colorectal cancer, and earlier work in metastatic breast cancer. Trials often combine pelareorep with chemotherapy or checkpoint inhibitors. A supply agreement exists with Roche Holding AG for atezolizumab. The FDA has granted Fast Track designation for both colorectal and pancreatic cancer indications.
Why Investors Follow ONCY
Interest stems mainly from pelareorep's potential as a differentiated immunotherapy. Oncology spending remains substantial, and approaches that could extend survival in difficult cancers like pancreatic disease address real unmet needs. In my view, the platform's ability to support multiple indications creates several possible catalysts as trials advance. When screening similar names, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key Risks to Consider
Substantial risks accompany any clinical-stage biotech. Operating losses have persisted since inception and are expected to continue. No guarantee exists that pelareorep will succeed in trials, gain approval, or reach commercialization. Competition from larger firms with greater resources is intense, and additional challenges include potential share dilution, reliance on contract organizations, regulatory hurdles, and typical small-cap healthcare volatility. From what I see, these factors warrant careful evaluation alongside any clinical progress.
Using AI Tools for Biotech Research
I have found Tickeron's AI Screener helpful when researching early-stage names like this. The platform lets users apply technical indicators, fundamentals, volatility measures, trends, AI signals, and industry filters to scan thousands of stocks efficiently. It provides a structured way to surface ideas that align with specific strategies without replacing deeper fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
ONCY in -13.11% downward trend, sliding for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONCY declined for three days, in 290 of 332 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for ONCY entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ONCY's RSI Indicator exited the oversold zone, 39 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for ONCY just turned positive on November 04, 2026. Looking at past instances where ONCY's MACD turned positive, the stock continued to rise in 34 of 48 cases over the following month. The odds of a continued upward trend are 71%.
Following a +15.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCY advanced for three days, in 148 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
ONCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.085) is normal, around the industry mean (3.498). P/E Ratio (-1.255) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ONCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products for the treatment of cancers
Industry Biotechnology
Advertisement